Clinical Trials
14 trialsNCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02215070 2021-11-17
Pasireotide in Prevention of GI Toxicity
Duke University
Phase 2 Completed
NCT01468532 2021-03-25
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT01372618 2017-12-27
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
NYU Langone Health
Phase 1/2 Terminated
NCT00929669 2017-11-28
LAR
University of Pennsylvania
Phase 2 Terminated
NCT01252251 2017-08-01
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01639352 2017-07-12
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Completed
NCT01620138 2016-08-22
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Universidade Federal do Rio de Janeiro
Phase 2/3 Completed
NCT01488487 2016-04-07
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00994110 2016-02-01
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00813592 2014-06-11
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
Phase 2 Terminated